HyGro
5 minutes ago
Well NWBO didn't have the confidence in their data to file it with the FDA. And let's see if MHRA believes it -- sure taking their time reviewing it. And even if MHRA approves it, it is the worst market for new, expensive oncology therapies. CAR-T, a well-established, proven treatment, took 5